BridgeBio Pharma, Inc. 8-K

What Happened
BridgeBio Pharma, Inc. (BBIO) reported positive Phase 3 topline results for oral infigratinib in achondroplasia in an 8-K filed on February 12, 2026. The company said the trial showed the first statistically significant improvements in body proportionality in achondroplasia. BridgeBio issued a press release with these topline results (attached as Exhibit 99.1 to the filing).

Key Details

• Filing date: February 12, 2026 (Form 8-K, Item 8.01 Other Events).
• Trial result: Positive Phase 3 topline data for oral infigratinib in achondroplasia with the first statistically significant improvements in body proportionality (as reported by the company).
• Press release: Title — “BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia” (attached as Exhibit 99.1).

Why It Matters
A positive Phase 3 topline readout is a material clinical milestone for BridgeBio: it can affect investor sentiment, the company’s clinical and regulatory plans, and potential future commercialization strategy for infigratinib in achondroplasia. Retail investors should review the company’s full press release and await detailed data and any subsequent regulatory guidance or filings for a clearer view of timing, safety profile, and commercial implications.